Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Submerged attached-growth reactors as lagoon retrofits for cold-weather ammonia removal: performance and sizing.

Mattson RR, Wildman M, Just C.

Water Sci Technol. 2018 Nov;78(8):1625-1632. doi: 10.2166/wst.2018.399.

PMID:
30500786
2.
3.

Patterns of regional lung physiology in cystic fibrosis using ventilation magnetic resonance imaging and multiple-breath washout.

Smith LJ, Collier GJ, Marshall H, Hughes PJC, Biancardi AM, Wildman M, Aldag I, West N, Horsley A, Wild JM.

Eur Respir J. 2018 Nov 8;52(5). pii: 1800821. doi: 10.1183/13993003.00821-2018. Print 2018 Nov.

PMID:
30361245
4.

Pragmatic criteria to define chronic pseudomonas aeruginosa infection among adults with cystic fibrosis.

Hoo ZH, Coates E, Maguire C, Cantrill H, Shafi N, Nash EF, McGowan A, Bourke SJ, Flight WG, Daniels TV, Nightingale JA, Allenby MI, Curley R, Wildman MJ.

Eur J Clin Microbiol Infect Dis. 2018 Nov;37(11):2219-2222. doi: 10.1007/s10096-018-3358-8. Epub 2018 Aug 18. No abstract available.

PMID:
30121804
5.

The importance of data issues when comparing cystic fibrosis registry outcomes between countries: Are annual review FEV1 in the UK only collected when subjects are well?

Hoo ZH, Curley R, Campbell MJ, Walters SJ, Wildman MJ.

J Eval Clin Pract. 2018 Aug;24(4):745-751. doi: 10.1111/jep.12967. Epub 2018 Jun 14.

6.

Role of habit in treatment adherence among adults with cystic fibrosis.

Hoo ZH, Gardner B, Arden MA, Waterhouse S, Walters SJ, Campbell MJ, Hind D, Maguire C, Dewar J, Wildman MJ.

Thorax. 2018 Jun 9. pii: thoraxjnl-2017-211453. doi: 10.1136/thoraxjnl-2017-211453. [Epub ahead of print]

PMID:
29886416
7.

Case Report: Dual nebulised antibiotics among adults with cystic fibrosis and chronic Pseudomonas infection.

Mann N, Murray S, Hoo ZH, Curley R, Wildman MJ.

Version 2. F1000Res. 2017 Dec 1 [revised 2018 Jan 1];6:2079. doi: 10.12688/f1000research.13298.2. eCollection 2017.

8.

Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision.

Hoo ZH, Edenborough FP, Curley R, Prtak L, Dewar J, Allenby MI, Nightingale JA, Wildman MJ.

Eur J Clin Microbiol Infect Dis. 2018 Apr;37(4):735-743. doi: 10.1007/s10096-017-3168-4. Epub 2018 Jan 6.

9.

Do cystic fibrosis centres with the lowest FEV1 still use the least amount of intravenous antibiotics? A registry-based comparison of intravenous antibiotic use among adult CF centres in the UK.

Hoo ZH, Campbell MJ, Curley R, Walters SJ, Wildman MJ.

J Cyst Fibros. 2018 May;17(3):360-367. doi: 10.1016/j.jcf.2017.10.005. Epub 2017 Oct 23.

10.

Rescue therapy within the UK Cystic Fibrosis Registry: An exploration of predictors of intravenous antibiotic use amongst adults with CF.

Hoo ZH, Wildman MJ, Curley R, Walters SJ, Campbell MJ.

Respirology. 2018 Feb;23(2):190-197. doi: 10.1111/resp.13174. Epub 2017 Sep 14.

11.

An empirical method to cluster objective nebulizer adherence data among adults with cystic fibrosis.

Hoo ZH, Campbell MJ, Curley R, Wildman MJ.

Patient Prefer Adherence. 2017 Mar 24;11:631-642. doi: 10.2147/PPA.S131497. eCollection 2017.

12.

Potential effect of centre size on continuity of care and healthcare performance.

Hoo ZH, Curley RE, Wildman MJ.

BMJ. 2017 Mar 27;356:j1514. doi: 10.1136/bmj.j1514. No abstract available.

13.

An Early Health Economic Analysis of the Potential Cost Effectiveness of an Adherence Intervention to Improve Outcomes for Patients with Cystic Fibrosis.

Tappenden P, Sadler S, Wildman M.

Pharmacoeconomics. 2017 Jun;35(6):647-659. doi: 10.1007/s40273-017-0500-x.

14.

Duration of intravenous antibiotic therapy in people with cystic fibrosis.

Plummer A, Wildman M, Gleeson T.

Cochrane Database Syst Rev. 2016 Sep 1;9:CD006682. doi: 10.1002/14651858.CD006682.pub5. Review.

PMID:
27582394
15.

Accurate reporting of adherence to inhaled therapies in adults with cystic fibrosis: methods to calculate "normative adherence".

Hoo ZH, Curley R, Campbell MJ, Walters SJ, Hind D, Wildman MJ.

Patient Prefer Adherence. 2016 May 23;10:887-900. doi: 10.2147/PPA.S105530. eCollection 2016.

16.

Promoting adherence to nebulized therapy in cystic fibrosis: poster development and a qualitative exploration of adherence.

Jones S, Babiker N, Gardner E, Royle J, Curley R, Hoo ZH, Wildman MJ.

Patient Prefer Adherence. 2015 Aug 3;9:1109-20. doi: 10.2147/PPA.S82896. eCollection 2015.

17.

Airway clearance techniques used by people with cystic fibrosis in the UK.

Hoo ZH, Daniels T, Wildman MJ, Teare MD, Bradley JM.

Physiotherapy. 2015 Dec;101(4):340-8. doi: 10.1016/j.physio.2015.01.008. Epub 2015 Mar 14.

18.

Regarding the article entitled "Iron supplementation does not worsen respiratory health or alter the sputum microbiome in cystic fibrosis".

Hoo ZH, Wildman MJ.

J Cyst Fibros. 2015 Jan;14(1):158-9. doi: 10.1016/j.jcf.2014.06.002. Epub 2014 Jun 25. No abstract available.

19.

Moving cystic fibrosis care from rescue to prevention by embedding adherence measurement in routine care.

Wildman MJ, Hoo ZH.

Paediatr Respir Rev. 2014 Jun;15 Suppl 1:16-8. doi: 10.1016/j.prrv.2014.04.007. Epub 2014 Apr 13. Review.

PMID:
24835307
20.

Exploration of the impact of 'mild phenotypes' on median age at death in the U.K. CF registry.

Hoo ZH, Wildman MJ, Teare MD.

Respir Med. 2014 May;108(5):716-21. doi: 10.1016/j.rmed.2014.02.012. Epub 2014 Mar 12.

21.

Successful use of haemodialysis to treat phenobarbital overdose.

Hoyland K, Hoy M, Austin R, Wildman M.

BMJ Case Rep. 2013 Nov 21;2013. pii: bcr2013010011. doi: 10.1136/bcr-2013-010011.

22.

Duration of intravenous antibiotic therapy in people with cystic fibrosis.

Plummer A, Wildman M.

Cochrane Database Syst Rev. 2013 May 31;(5):CD006682. doi: 10.1002/14651858.CD006682.pub4. Review.

PMID:
23728662
23.

Intravenous iron among cystic fibrosis patients.

Hoo ZH, Wildman MJ.

J Cyst Fibros. 2012 Dec;11(6):560-2. doi: 10.1016/j.jcf.2012.05.002. Epub 2012 Jun 19. No abstract available.

24.

Duration of intravenous antibiotic therapy in people with cystic fibrosis.

Plummer A, Wildman M.

Cochrane Database Syst Rev. 2011 Jan 19;(1):CD006682. doi: 10.1002/14651858.CD006682.pub3. Review. Update in: Cochrane Database Syst Rev. 2013;5:CD006682.

PMID:
21249681
25.

Predicting mortality for patients with exacerbations of COPD and Asthma in the COPD and Asthma Outcome Study (CAOS).

Wildman MJ, Sanderson C, Groves J, Reeves BC, Ayres J, Harrison D, Young D, Rowan K.

QJM. 2009 Jun;102(6):389-99. doi: 10.1093/qjmed/hcp036. Epub 2009 Apr 15.

PMID:
19369483
26.

Survival and quality of life for patients with COPD or asthma admitted to intensive care in a UK multicentre cohort: the COPD and Asthma Outcome Study (CAOS).

Wildman MJ, Sanderson CF, Groves J, Reeves BC, Ayres JG, Harrison D, Young D, Rowan K.

Thorax. 2009 Feb;64(2):128-32. doi: 10.1136/thx.2007.091249. Epub 2008 Oct 13.

PMID:
18852157
27.

Duration of intravenous antibiotic therapy in people with cystic fibrosis.

Fernandes B, Plummer A, Wildman M.

Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006682. doi: 10.1002/14651858.CD006682.pub2. Review. Update in: Cochrane Database Syst Rev. 2011;(1):CD006682.

PMID:
18425963
29.
30.

Experimental evidence from H/D exchange studies for the failure of direct C-C coupling mechanisms in the methanol-to-olefin process catalyzed by HSAPO-34.

Marcus DM, McLachlan KA, Wildman MA, Ehresmann JO, Kletnieks PW, Haw JF.

Angew Chem Int Ed Engl. 2006 May 5;45(19):3133-6. No abstract available.

PMID:
16570333
31.

Socioeconomic status and outcome from intensive care in England and Wales.

Hutchings A, Raine R, Brady A, Wildman M, Rowan K.

Med Care. 2004 Oct;42(10):943-51.

PMID:
15377926
32.

Sources of variability in uncertain medical decisions in the ICU: a process tracing study.

Kostopoulou O, Wildman M.

Qual Saf Health Care. 2004 Aug;13(4):272-80.

33.

Variations in mortality in acute COPD may reflect nihilism as well as resources.

Wildman MJ.

Thorax. 2004 Jun;59(6):538; author reply 538. No abstract available.

34.

Variation in intubation decisions for patients with chronic obstructive pulmonary disease in one critical care network.

Wildman MJ, O'Dea J, Kostopoulou O, Tindall M, Walia S, Khan Z.

QJM. 2003 Aug;96(8):583-91.

PMID:
12897344
35.

Q fever: still a mysterious disease.

Wildman MJ, Ayres JG.

QJM. 2002 Dec;95(12):833-4. No abstract available.

PMID:
12524714
36.

GABA-like immunoreactivity in nonspiking interneurons of the locust metathoracic ganglion.

Wildman M, Ott SR, Burrows M.

J Exp Biol. 2002 Dec;205(Pt 23):3651-9.

37.

Long-term follow-up of patients from the 1989 Q fever outbreak: no evidence of excess cardiac disease in those with fatigue.

Ayres JG, Wildman M, Groves J, Ment J, Smith EG, Beattie JM.

QJM. 2002 Aug;95(8):539-46.

PMID:
12145393
38.

Chronic fatigue following infection by Coxiella burnetii (Q fever): ten-year follow-up of the 1989 UK outbreak cohort.

Wildman MJ, Smith EG, Groves J, Beattie JM, Caul EO, Ayres JG.

QJM. 2002 Aug;95(8):527-38.

PMID:
12145392
40.

RDX degradation using an integrated Fe(0)-microbial treatment approach.

Wildman MJ, Alvarez PJ.

Water Sci Technol. 2001;43(2):25-33.

PMID:
11380187
41.

A case-controlled study with dornase alfa to evaluate impact on disease progression over a 4-year period.

Shah PL, Conway S, Scott SF, Rainisio M, Wildman M, Stableforth D, Hodson ME.

Respiration. 2001;68(2):160-4.

PMID:
11287830
42.
43.
44.
45.

Haemolytic anaemia following treatment with piperacillin in a patient with cystic fibrosis.

Thickett KM, Wildman MJ, Fegan CD, Stableforth DE.

J Antimicrob Chemother. 1999 Mar;43(3):435-6. No abstract available.

PMID:
10223610
46.

Quality and the invisible man.

Wildman M.

BMJ. 1998 Dec 12;317(7173):1667. No abstract available.

47.
48.
49.

Sensory characteristics of the P afferent neurone of the crab thoracic-coxal muscle receptor organ.

Wildman MH, Cannone AJ.

J Comp Physiol A. 1996 Aug;179(2):277-89.

PMID:
8765562
50.

Interaction between afferent neurones in a crab muscle receptor organ.

Wildman MH, Cannone AJ.

Brain Res. 1991 Nov 22;565(1):175-8.

PMID:
1773354

Supplemental Content

Loading ...
Support Center